pcn poster

Posters

A Thorough QT Trial Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization

Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder (ADHD). The effect of centanafadine on car...

Osman Turkoglu , MD;

10/26/2023

"When Perception Deceives: Unmasking Bilateral Occipito-Parietal Infarcts Presenting as Complex Hallucinations and Self-Harm"

Case of a 51-year-old veteran with no prior psychiatric history who presented to the ED with self-inflicted injury and positive symptoms (both CAH, VH), and was transferred to inpatient p...

Jaberpreet Dhaliwal , DO;

10/26/2023

“When was your last bowel movement?” A Case Study on Treatment Resistant Constipation in a Patient on Clozapine

This poster is a case study on demonstrating the utility of using Lubiprostone to treat Clozapine-induced treatment resistant constipation.

Jessica Frihart , MSN, CNS, PHMNP-BC;

10/26/2023

52-Week Open-Label Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...

Jessica McDonough , MD;

10/26/2023

A case of acute intermittent porphyria attack with psychiatric symptoms in a female resolving with the removal of stressors and lack of medical treatment

This poster addresses a case of a middle-aged female with known acute intermittent porphyria and substance use disorder presenting with psychotic symptoms. During her hospitalization, she...

Madison Dew ;

10/26/2023

A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).

Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...

Ann Childress , MD;

10/26/2023

A Pilot Study to Assess if Patients With Schizophrenia Can Form a Working Alliance With a Digital Therapeutic

Use of digital therapeutics has increased in recent years, but it is unclear if patients can establish an effective therapeutic digital working alliance (DWA) with digital therapeutic. In...

Nathan Mitchell , PhD;

10/26/2023

A Psychiatric Drug Prescription Framework to Predict Drug-Drug Interaction Risks with Artificial Intelligence

Using AI to streamline complex psychiatric drug prescriptions for more effective and safe clinical prognosis.

Danielle Wang ;

10/26/2023

Exposure-Response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluat...

Srdjan Stankovic , MD, MSPH;

Julie Passarell , MA;

Becky Howell , MA, MBA;

Joel Owen , PhD;

Mona Darwish , PhD;

Bryan Dirks , MD, MSc, MBA;

10/27/2020

ENHANCE Trial: Adherence to Current Antipsychotic and Adjunctive Pimavanserin in Patients With Schizophrenia and Inadequate Response to Antipsychotic Treatment

Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffec...

Brandon Abbs , PhD;

Mona Darwish , PhD;

Dragana Bugarski-Kirola , MD, MBA, MSc;

Yuan Liu , MSc;

Srdjan Stankovic , MD, MSPH;

10/27/2020

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products